Re: OB: Still More 17 alpha hydroxy Progesterone
From: art fougner, md (evsono@pipeline.com)
Tue Feb 1 09:54:27 2005
i believe the Woolley Mammoth still languishes in his Pleistocene
prison, the last casualty of Sept 11.
art
At Tue, 1 Feb 2005, Meenan, Anna, Kevin wrote:
>
>And where is Luis these days? Too busy doing
>meta-analyses to post to the list anymore?
>According to the search engine, it's been YEARS
>since he posted here. And BTW, where is Bernard
>Cristalli? Another former poster who hasn't
>posted in years. Anyone else we haven't heard
>from in awhile?
>
> Anna Meenan, MD
>
>>More from the Feb Green Journal - Luis Sanchez-Ramos - a contributor to
>>this list co-authors this one -
>>
>>Progestational Agents to Prevent Preterm Birth: A Meta-Analysis of
>>Randomized Controlled Trials
>>Luis Sanchez-Ramos, MD, Andrew M. Kaunitz, MD and Isaac Delke, MD
>>
>>>From the Department of Obstetrics and Gynecology, Division of
>>MaternalñFetal Medicine, University of Florida Health Science Center,
>>Jacksonville, Florida.
>>
>>OBJECTIVE: To perform an updated systematic review with meta-analysis to
>>further elucidate the efficacy of progestational agents for the
>>prevention of preterm births in patients at elevated risk.
>>
>>DATA SOURCES: Computerized databases, references in published studies,
>>and textbook chapters in all languages were used to identify randomized
>>controlled trials (RCTs) evaluating the use of progestational agents for
>>the prevention of preterm births in women at elevated risk.
>>
>>METHODS OF STUDY SELECTION: We identified RCTs that compared
>>progestational agents with placebo for patients at risk for preterm
>>birth and evaluated at least one of the following: delivery before 37
>>weeks of gestation, birth weight less than 2,500 g, threatened preterm
>>labor, respiratory distress syndrome, and perinatal mortality. The
>>primary outcomes assessed were preterm delivery and perinatal mortality.
>>
>>TABULATION, INTEGRATION, AND RESULTS: Ten studies met inclusion criteria
>>for this review. For each study with binary outcomes, an odds ratio
>>(OR) with 95% confidence intervals (CIs) was calculated for selected
>>outcomes. Homogeneity was tested across the studies. Compared with
>>women allocated to receive placebo, those who received progestational
>>agents had lower rates of preterm delivery (26.2% versus 35.9%; OR 0.45,
>>95% CI 0.25ñ0.80). Similar results were noted when comparing patients
>>who were specifically treated with 17{alpha}-hydroxyprogesterone
>>caproate (29.3% versus 40.9%; OR 0.45, 95% CI 0.22ñ0.93). Additionally,
>>subjects allocated to receive 17{alpha}-hydroxyprogesterone caproate had
>>lower rates of birth weights less than 2,500 g (OR 0.50, 95% CI
>>0.36ñ0.71). No differences in rates of hospital admissions for
>>threatened preterm labor or perinatal mortality were noted for subjects
>>receiving progestational agents in general or for those receiving only
>>17{alpha}-hydroxyprogesterone caproate specifically.
>>
>>CONCLUSION: The use of progestational agents and
>>17{alpha}-hydroxyprogesterone caproate reduced the incidence of preterm
>>birth and low birth weight newborns.
>>
>>art
>>
>>--
>>art fougner, md
>>
>> "If you don't know where you are going, you will wind up somewhere else."
>>Lawrence Peter Berra
--
art fougner, md
"If you don't know where you are going, you will wind up somewhere else."
Lawrence Peter Berra
|
|
